Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: Joint experience of the MD Anderson Cancer Center and Duke University Medical Center

Cancer

Volumn 119, Issue 17, 2013, Pages 3177-3185

  Falchi, Lorenzo ^a   Keating, Michael J ^a   Wang, Xuemei ^a   Coombs, Catherine C ^b   Lanasa, Mark C ^b   Strom, Sara ^a   Wierda, William G ^a   Ferrajoli, Alessandra ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

African Americans; Chemoimmunotherapy; Chronic Lymphocytic Leukemia; Prognostic Factors; Racial Disparities; Survival

Indexed keywords

ALEMTUZUMAB; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; IMMUNOGLOBULIN HEAVY CHAIN; MITOXANTRONE; PENTOSTATIN; PROTEIN KINASE ZAP 70; RITUXIMAB;

ADULT; AFRICAN AMERICAN; AGED; APLASTIC ANEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DEMENTIA; DISEASE EXACERBATION; EVENT FREE SURVIVAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RACE DIFFERENCE; SEX DIFFERENCE; SUICIDE; TREATMENT RESPONSE;

AFRICAN AMERICANS; CHEMOIMMUNOTHERAPY; CHRONIC LYMPHOCYTIC LEUKEMIA; PROGNOSTIC FACTORS; RACIAL DISPARITIES; SURVIVAL;

ACADEMIC MEDICAL CENTERS; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; BETA 2-MICROGLOBULIN; CHROMOSOMES, HUMAN, PAIR 17; DISEASE-FREE SURVIVAL; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEALTH STATUS DISPARITIES; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; NORTH CAROLINA; RISK ASSESSMENT; RISK FACTORS; TEXAS; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84882569581     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28030     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer statistics for African Americans. CA Cancer J Clin. 2002; 52: 23-47.
3. Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011; 117: 2530-2540.
4. Evens AM, Antillon M, Aschebrook-Kilfoy B, Chiu BCH,. Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. Ann Oncol. 2012; 23: 2128-2137.
5. Flowers CR, Fedewa SA, Chen AY, et al. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prevent. 2012; 21: 1520-1530.
6. Goggins WB, Lo FFK,. Racial and ethnic disparities in survival of US children with acute lymphoblastic leukemia: evidence from the SEER database 1988-2008. Cancer Causes Control. 2012; 23: 737-743.
7. Keegan TH, Moy LM, Foran JM, et al. Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study [published online ahead of print September 28, 2012]. Leuk Lymphoma. 2012.
8. Patel MI, Ma Y, Mitchell BS, Rhoads KF,. Understanding disparities in leukemia: a national study. Cancer Causes Control. 2012; 23: 1831-1837.
9. Coombs CC, Falchi L, Weinberg JB, Ferrajoli A, Lanasa MC,. Chronic lymphocytic leukemia in African Americans. Leuk Lymphoma. 2012; 53: 2326-2329.
10. Murthy VH, Krumholz HM, Gross CP,. G. Participation in cancer clinical trials race-, sex-, and age-based disparities. JAMA. 2004; 291: 2720-2726.
11. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 78-93.
12. Davies S,. Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet? Hematology Am Soc Hematol Educ Program. 2006: 111-117.
13. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007; 139: 809-819.
14. Shenoy PJ, Malik N, Sinha R, et al. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk. 2011; 11: 498-506.
15. Rai K, Sawitsky A, Cronkite E, Chanana A, Levy R, Pasternack B,. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46: 219-234.
16. Cheson B, Bennett J, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997.
17. Kaplan E, Meier P,. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
18. Mantel N,. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
19. Cox D,. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187-220.
20. Alcalai R, Ben-Yehuda D, Ronen I, Paltiel O,. Ethnicity and prognosis in acute myeloid leukemia. Am J Hematol. 2003; 72: 127-134.
21. Sekeres MA, Peterson B, Dodge RK, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004; 103: 4036-4042.
22. Rubnitz JE, Lensing S, Razzouk BI, Pounds S, Pui C-H, Ribeiro RC,. Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience. Pediatr Blood Cancer. 2007; 48: 10-15.
23. Bhatia S,. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002; 100: 1957-1964.
24. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG,. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA. 2003; 290: 2008-2014.
25. Keegan THM, Clarke CA, Chang ET, Shema SJ, Glaser SL,. Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer Causes Control. 2009; 20: 1881-1892.
26. Kent EE, Morris RA, Largent JA, Ziogas A, Sender LS, Anton-Culver H,. Socioeconomic impacts on survival differ by race/ethnicity among adolescents and young adults with non-Hodgkin's lymphoma. J Cancer Epidemiol. 2010; 2010: 1-10.
27. Kent EE, Sender LS, Largent JA, Anton-Culver H,. Leukemia survival in children, adolescents, and young adults: influence of socioeconomic status and other demographic factors. Cancer Causes Control. 2009; 20: 1409-1420.
28. Friese CR, Earle CC, Magazu LS, et al. Timeliness and quality of diagnostic care for Medicare recipients with chronic lymphocytic leukemia. Cancer. 2011; 117: 1470-1477.
29. Sekeres M, Elson P, Kalaycio M, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009; 113: 28-36.
30. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB,. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002; 287: 2106-2113.